Kailera Therapeutics (NASDAQ:KLRA) Issues Quarterly Earnings Results

Kailera Therapeutics (NASDAQ:KLRA) announced its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.81, FiscalAI reports.

Kailera Therapeutics Price Performance

Shares of NASDAQ KLRA traded up $0.22 during mid-day trading on Wednesday, hitting $12.80. The company had a trading volume of 651,265 shares, compared to its average volume of 885,357. The firm has a market capitalization of $1.66 billion and a P/E ratio of -0.00. Kailera Therapeutics has a 1 year low of $9.76 and a 1 year high of $28.23. The business’s 50-day simple moving average is $13.11.

Institutional Trading of Kailera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. increased its holdings in shares of Kailera Therapeutics by 31.1% in the 3rd quarter. Alps Advisors Inc. now owns 171,739 shares of the company’s stock worth $1,961,000 after buying an additional 40,739 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Kailera Therapeutics during the 3rd quarter worth $134,000. Profund Advisors LLC bought a new stake in shares of Kailera Therapeutics during the 3rd quarter worth $216,000. Mirador Capital Partners LP purchased a new position in Kailera Therapeutics in the third quarter worth $666,000. Finally, State Street Corp purchased a new position in Kailera Therapeutics in the second quarter worth $19,126,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.75.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.